Frontlight ResearchEarly access
Lung cancer trials in Singapore
43 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Singapore
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - Phase 1Taking peoplePhase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Where
- Singapore
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07261631 - Phase 2/3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Singapore
- Age
- 18 years and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Kent Ridge, Singapore
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 3Taking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Singapore
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - Phase 1/2Taking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Singapore
- Age
- 12 years and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Singapore
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 1/2Taking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Singapore
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - Phase 2Taking peopleAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- Singapore
- Age
- 18 years to 70 years
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - Phase 1/2Taking peopleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Singapore
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 1/2Taking peopleA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- Where
- Singapore
- Age
- 18 years and over
- People
- 398 worldwide
- Run by
- Hummingbird Bioscience
See details and how to joinNCT05910827 - No phaseTaking peopleSingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)
- Where
- Singapore
- Age
- 50 years to 80 years
- People
- 1,000
- Run by
- National Cancer Centre, Singapore
See details and how to joinNCT05724264 - Phase 1CompletedPhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Where
- Singapore
- Age
- 18 years and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00 - No phaseTaking peopleLiquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
- Where
- Singapore
- Age
- 21 years to 75 years
- People
- 140
- Run by
- National University Hospital, Singapore
See details and how to joinNCT07358715 - No phaseTaking peopleOsimertinib for Advanced EGFR-positive NSCLC Patients
- Where
- Singapore
- Age
- 21 years to 99 years
- People
- 58
- Run by
- National University Hospital, Singapore
See details and how to joinNCT05037331 - Phase 2Taking peopleAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Where
- Singapore
- Age
- 18 years and over
- People
- 497 worldwide
- Run by
- Apollomics Inc.
See details and how to joinNCT03175224 · EU 2024-514542-37-00 - No phaseTaking peopleA Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
- Where
- Singapore
- Age
- 21 years to 99 years
- People
- 600 worldwide
- Run by
- National Cancer Centre, Singapore
See details and how to joinNCT06418412 - Phase 2Taking peopleA Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
- Where
- Singapore
- Age
- 21 years to 99 years
- People
- 360
- Run by
- National University Hospital, Singapore
See details and how to joinNCT06422403